Getting a medicine into the right organ does not guarantee it will act only on diseased cells. SRTD Biotech, a drug-development startup in Jülich, Germany, has raised €31.5 million to pursue more selective RNA medicines. RNA is a molecule that can carry instructions for making proteins. The company says its designs recognize signs of disease inside cells and activate those instructions there, aiming to limit exposure in healthy tissue.
The funding will support preclinical development: laboratory and other work before human trials. SRTD is pursuing potential treatments for cancer, diseases in which the immune system attacks the body, and conditions involving tissue scarring. The approach remains experimental. Its promise depends on a precise distinction: recognizing disease from signals inside a cell, then activating the treatment there.
Source · merieux-partners.com ↗
